Login
Companies $ONC
$411.29 -$5.25 (1.26%) Live
BeOne Medicines Ltd. logo

BeOne Medicines Ltd.

beonemedicines.com

What Do They Do?

Sells cancer medicines for blood and solid tumors to hospitals, pharmacies and other health care providers.

How Do They Make Money?

Product sales account for 99% of revenue; the company sells medicines to distributors, pharmacies and hospitals, earning revenue when products are delivered and customers pay afterward.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Product revenue, net
Sold outright

99%
FY2022: 89%
Other revenue
1.1%
FY2022: 11%

Who Are Their Customers?

In the U.S., specialty pharmacies and distributors buy medicines for resale to health care providers and patients; in Europe, sales go through distributors or directly to hospitals. In China, distributors buy products and resell them to hospitals or pharmacies.

Do Revenues Turn Into Profits?

Yes. It kept 5 cents of every revenue dollar as net income in FY2025 and turned 18 cents into free cash flow.

Operating income, FY2025
8% of revenue
▲ Turned profitable vs FY2024 (−$568.2M, −15%)
Net income, FY2025
5% of revenue
▲ Turned profitable vs FY2024 (−$644.8M, −17%)
Free cash flow, FY2025
18% of revenue
▲ Turned profitable vs FY2024 (−$633.3M, −17%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +34%
vs $1.4B in Q3 FY2025
Net income
▲ +208%
vs $124.8M in Q3 FY2025
Product revenue, net share of revenue vs 98.8% in Q3 FY2025
  • May 15, 2026 FDA approves BEQALZI for mantle cell lymphoma The accelerated approval covers adults with relapsed or refractory disease after prior systemic treatment, including a BTK inhibitor.

Growing. Revenue grew 4.5x in 4 years, from $1.2B in FY2021 to $5.3B in FY2025, about 46% a year.

An additional approved medicine The older report described BRUKINSA, tislelizumab and pamiparib as approved in-house medicines; the latest reports sonrotoclax’s first approval, expanding the commercial portfolio.

Broader commercial rights The older report listed tislelizumab commercial rights outside North America, Japan, the EU and certain European markets; the latest lists global commercial rights for TEVIMBRA.

Revenue over time
Product revenue, net Other revenue
$10B$5B$0

Who Do They Compete With?

Competes with AbbVie, Janssen, AstraZeneca, Eli Lilly, Innocare, Merck, Bristol Myers Squibb, Roche, Merck KGaA, Regeneron, Sanofi, GSK, Junshi, Henlius, Ascentage Pharma, and Nurix Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support